Henry I. Miller

Henry I. Miller M.D. is a Senior research fellow at the Hoover Institution which champions the free market and limited government.

Miller was able to put these principles into practice as an official at the Food and Drug Administration from 1979-1994 during which time he served in a number of posts involved with biotechnology. According to his Hoover Institution home page, "He was the medical reviewer for the first genetically engineered drugs evaluated by the FDA and was instrumental in the rapid licensing of human insulin and human growth hormone."(emphasis added) He served in several posts, including "special assistant to the FDA commissioner, with responsibility for biotechnology issues". From 1989 to 1994, he was the "founding director of the FDA's Office of Biotechnology".

Miller is a member of the UN's Codex Alimentarius committee on GM foods. He is also a key figure in the network of right-wing pro-biotech lobby groups in the U.S. He is an 'adjunct scholar' at the Competitive Enterprise Institute, a director of the American Council on Science and Health and a director of Consumer Alert. He was also part of the pro-GM/anti-organic 'No More Scares' group with Michael Fumento, Steven Milloy and ACSH's Elizabeth Whelan.

He has authored a number of articles and monographs on GM foods, including Biotechnology Regulation: The Unacceptable Costs of Excessive Regulation. He has also co-authored a number of articles with Greg Conko of the Competitive Enterprise Institute which suggest that concerns about the safety of GM food are really due to "trade protectionism" and "anti-science fearmongering" and that GMOs require, if anything, less regulation, not more.

Miller has blamed the industry itself for the public mistrust of biotechnology, "In this area, the U.S. government agencies have done exactly what big agribusiness has asked them to do and told them to do," he told the New York Times.. The problem for Miller does not seem to be the industry capture of government regulation but that it was publicly exposed.

It has been suggested that for Miller bringing a product to market quickly is more important than ensuring its safety. Miller counters with the claim that genetic engineering is a particularly safe and precise process and that genetically engineered products are therefore being unnecessarily over-regulated, something that is limiting the true potential of the technology. He told the New York Times, "Food biotech is dead... The potential now is an infinitesimal fraction of what most observers had hoped it would be."